"Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes"
In 2021, it gained FDA approval for chronic weight management under the name Wegovy, representing a significant advancement in obesity treatment options
Patients with a BMI of 30, or a BMI of 27 with one weight-related medical condition (like high blood pressure or type 2 diabetes), are candidates for weight loss medications like GLP-1s
These medications affect multiple systems: they delay gastric emptying, increase satiety, and interact with brain centers involved in hunger and reward
Insights on Effective Medical Weight Loss by Kelli Marchewka How do Liraglutide and Semaglutide GLP-1 differ
As glycaemia already underwent alterations following certain Ex9 injections (prior to the administration of glucose, WD group), the AUC was measured from the baseline (before central injections) through the conclusion of OGTTs (t120) in all tested conditions